Table 2 ED 50s & 90s of Doxovirâ„¢ to Adenovirus Type 5. Effective dose (ED) 50s and 90s of Doxovirâ„¢ (CTC-96) against Adenovirus type 5 in HeLa (human cervical carcinoma), A549 (human cervical carcinoma) and SIRC (rabbit corneal) cells during Virucidal, Antiviral and Viral Inactivation assays.
|  |  | (MIC 50 (μg/ml) | (MIC 90 (μg/ml) | ||||
|---|---|---|---|---|---|---|---|
HeLa (human cervical carcinoma) | Virucidal | 33.0 | ± | 6.9 | 46.6 | ± | 9.7 |
|  | Antiviral | 4.5 | ± | 0.1 | 21.8 | ± | 1.2 |
|  | Viral Inactivation | 16.5 | ± | 2.5 | 43.0 | ± | 1.3 |
A549 (human lung carcinoma) | Virucidal | 31.7 | ± | 1.9 | 46.3 | ± | 2.6 |
|  | Antiviral | 4.7 | ± | 0.2 | 20.8 | ± | 1.9 |
|  | Viral Inactivation | 4.2 | ± | 1.1 | 37.5 | ± | 6.5 |
SIRC (rabbit cornea) | Virucidal | 13.6 | ± | 2.3 | 22.7 | ± | 3.5 |
|  | Antiviral | 27.3 | ± | 8.3 | 45.5 | ± | 1.6 |
|  | Viral Inactivation | 13.1 | ± | 2.9 | 23.9 | ± | 4.9 |